← All trials
NCT06320431
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 26, 2024
- Primary completion
- Sep 30, 2030
- Completion date
- Dec 31, 2030
- First posted
- Mar 20, 2024
- Last posted
- Oct 1, 2024
- Enrollment
- 4000
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CalgaryLead sponsor
- University of CalgaryOfficial
- University of New South WalesOfficial
- University of CalgarySponsor investigator
- University of New South WalesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.